Treating Anemia of CKD: Moving from ESAs to Oral Options

Friday, April 14, 2023 | 6:45 AM - 8:30 AM
Click Here to complete the Evaluation

Thank you for attending this symposium.  You are not required to complete this evaluation to earn CME/CE credit/contact hours for this symposium.  However, your feedback is important to us, and your responses will assist us in developing future programs.

After attending this symposium, the participants in this educational activity will be able to:

  • Assess the clinical implications of the recommendations of and challenges recognized by the December 2021 KDIGO Controversies Conference on Novel Anemia Therapies in CKD
  • Relate the role of HIF-PHI in anemia associated with CKD to the rationale for developing therapies that targets PH inhibition
  • Evaluate the clinical implications of emerging data and clinical implications of PH inhibition as a strategy to address anemia in CKD

Supporter
This activity is supported by an educational grant from GSK.

Evaluation for Treating Anemia of CKD: Moving from ESAs to Oral Options

Please enable JavaScript in your browser to complete this form.
Name
Which social determinant of health (SDoH) do you most commonly see among your patients? Select one only.
In your estimate, what percentage of your patients has the SDoH you selected that impacts your treatment decisions?
On average, how many individuals with CKD, including those receiving dialysis or a transplant, do you see every month?
Rate your agreement with the following statement(s):
Strongly DisagreeDisagreeNeutralAgreeStrongly Agree
My confidence regarding the rationale and need of emerging therapies that target PH inhibition for patients with anemia and CKD has improved as a result of my participation in this activity
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
How often did you implement the following strategies BEFORE participating in this activity? (select all that apply)
NeverInfrequentlySometimesFrequentlyAlways
Apply the multifactoral pathophysiology of anemia to determine best treatment of patients with CKD
Never
Infrequently
Sometimes
Frequently
Always
Administer the latest clinical evidence of current and emerging therapeutic options for anemia among patients with CKD
Never
Infrequently
Sometimes
Frequently
Always
Establish the use of interprofessional care teams in order to manage patients with anemia and CKD
Never
Infrequently
Sometimes
Frequently
Always
How often do you intend to implement them AFTER participating? (select all that apply)
NeverInfrequentlySometimesFrequentlyAlways
Apply the multifactoral pathophysiology of anemia to determine best treatment of patients with CKD
Never
Infrequently
Sometimes
Frequently
Always
Administer the latest clinical evidence of current and emerging therapeutic options for anemia among patients with CKD
Never
Infrequently
Sometimes
Frequently
Always
Establish the use of interprofessional care teams in order to manage patients with anemia and CKD
Never
Infrequently
Sometimes
Frequently
Always
Is there information from this activity that was especially helpful or lacking for your patients?
Scroll to Top